Cimadamore A.; Massari F.; Santoni M.; Lopez-Beltran A.; Cheng L.; Scarpelli M.; Montironi R.; Moch H., PD1 and PD-L1 inhibitors for the treatment of kidney cancer: The role of PD-L1 assay, «CURRENT DRUG TARGETS», 2020, 21, pp. 1664 - 1671 [articolo]
Santoni M.; Massari F.; Cheng L.; Cimadamore A.; Scarpelli M.; Montironi R.; Lopez-Beltran A., Pd-l1 inhibitors for the treatment of prostate cancer, «CURRENT DRUG TARGETS», 2020, 21, pp. 1558 - 1565 [articolo]
Lamberti, Giuseppe; Brizzi, Maria Pia; Pusceddu, Sara; Gelsomino, Fabio; Di Meglio, Giovanni; Massari, Francesco; Badalamenti, Giuseppe; Riccardi, Ferdinando; Ibrahim, Toni; Ciccarese, Chiara; Buti, Sebastiano; Carnaghi, Carlo; Prinzi, Natalie; Panzuto, Francesco; Campana, Davide, Perioperative Chemotherapy in Poorly Differentiated Neuroendocrine Neoplasia of the Bladder: A Multicenter Analysis, «JOURNAL OF CLINICAL MEDICINE», 2020, 9, Article number: 1351, pp. 1 - 12 [articolo]Open Access
Petrylak D.P.; de Wit R.; Chi K.N.; Drakaki A.; Sternberg C.N.; Nishiyama H.; Castellano D.; Hussain S.A.; Flechon A.; Bamias A.; Yu E.Y.; van der Heijden M.S.; Matsubara N.; Alekseev B.; Necchi A.; Geczi L.; Ou Y.-C.; Coskun H.S.; Su W.-P.; Bedke J.; Gakis G.; Percent I.J.; Lee J.-L.; Tucci M.; Semenov A.; Laestadius F.; Peer A.; Tortora G.; Safina S.; Garcia del Muro X.; Rodriguez-Vida A.; Cicin I.; Harputluoglu H.; Tagawa S.T.; Vaishampayan U.; Aragon-Ching J.B.; Hamid O.; Liepa A.M.; Wijayawardana S.; Russo F.; Walgren R.A.; Zimmermann A.H.; Hozak R.R.; Bell-McGuinn K.M.; Powles T.; Wong S.-L.S.; Tan T.H.; Hovey E.J.; Clay T.D.; Wan Ng S.S.; Rutten A.; Machiels J.-P.; Dumez H.; Cheng S.Y.-S.; Ferrario C.; Sengeloev L.; Jensen N.V.; Thibault C.; Laguerre B.; Joly F.; Culine S.; Becht C.; Niegisch G.; Stockle M.; Grimm M.-O.; Schwentner C.A.; Schultze-Seemann W.; Kalofonos H.; Mavroudis D.; Papandreou C.; Karavasilis V.; Revesz J.; Rosenbaum E.; Leibowitz-Amit R.; Kejzman D.; Sarid , Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial, «THE LANCET ONCOLOGY», 2020, 21, pp. 105 - 120 [articolo]
Mollica V.; Rizzo A.; Massari F., Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?, «EUROPEAN UROLOGY ONCOLOGY», 2020, 3, pp. 559 - 560 [articolo]
Di Nunno V.; Santoni M.; Gatto L.; Mollica V.; Massari F., Re: Christopher C. Parker, Nicholas D. James, Christopher D. Brawley, et al. Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial. Lancet 2018;392:2353-66: Metastatic Hormone-naïve Prostate Cancer: A Multimodal Approach for a Heterogeneous Disease, «EUROPEAN UROLOGY ONCOLOGY», 2020, 3, pp. 390 - 390 [articolo]
Rizzo A.; Mollica V.; Massari F., Re: Hanbing Song, Bobak Seddighzadeh, Matthew R. Cooperberg, Franklin W. Huang. Expression of ACE2 and TMPRSS2, the SARS-CoV-2 Receptor and Co-Receptor, in Prostate Epithelial Cells. Eur Urol. In press DOI: 10.1016/j.eururo.2020.04.065, «JOURNAL OF CLEANER PRODUCTION», 2020, 78, pp. 205 - 206 [articolo]
Rizzo A.; Mollica V.; Massari F., Re: Maha Hussain, Joaquin Mateo, Karim Fizazi, et al. Survival with Olaparib in Metastatic Castration-resistant Prostate Cancer. N Engl J Med. In press. https://doi.org/10.1056/NEJMoa2022485, «EUROPEAN UROLOGY ONCOLOGY», 2020, 3, pp. 806 - 806 [articolo]
Rizzo A.; Mollica V.; Massari F., Re: Nizar M. Tannir, Sabina Signoretti, Toni K. Choueiri, et al. Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clin Cancer Res. In press. https://doi.org/10.1158/1078-0432.ccr-20-2063, «EUROPEAN UROLOGY ONCOLOGY», 2020, 3, pp. 804 - 805 [articolo]
Massari, F; Mollica, V, Re: Platinum-based Chemotherapy in Metastatic Prostate Cancer with DNA Repair Gene Alterations, «EUROPEAN UROLOGY», 2020, 78, pp. 768 - 770 [articolo]
Mollica V.; Rizzo A.; Massari F., Re: Toni K. Choueiri, Daniel Y.C. Heng, Jae Lyun Lee, et al. Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma: The SAVOIR Phase 3 Randomized Clinical Trial. JAMA Oncol. In press. https://doi.org/10.1001/jamaoncol.2020.2218: SAVOIR: From Own Goal to Winning Goal?, «EUROPEAN UROLOGY ONCOLOGY», 2020, 3, pp. 561 - 562 [articolo]
Santoni M.; Heng D.Y.; Bracarda S.; Procopio G.; Milella M.; Porta C.; Matrana M.R.; Carteni G.; Crabb S.J.; De Giorgi U.; Basso U.; Masini C.; Calabro F.; Vitale M.G.; Santini D.; Massari F.; Galli L.; Fornarini G.; Ricotta R.; Buti S.; Zucali P.; Caffo O.; Morelli F.; Carrozza F.; Martignetti A.; Gelibter A.; Iacovelli R.; Mosca A.; Atzori F.; Vau N.; Incorvaia L.; Ortega C.; Scarpelli M.; Lopez-Beltran A.; Cheng L.; Paolucci V.; Graham J.; Pierce E.; Scagliarini S.; Sepe P.; Verzoni E.; Merler S.; Rizzo M.; Sorgentoni G.; Conti A.; Piva F.; Cimadamore A.; Montironi R.; Battelli N., Real-world data on cabozantinib in previously treated patients with metastatic renal cell carcinoma: Focus on sequences and prognostic factors, «CANCERS», 2020, 12, Article number: 84, pp. 1 - 13 [articolo]Open Access
Aurilio G.; Santoni M.; Cimadamore A.; Massari F.; Scarpelli M.; Lopez-Beltran A.; Cheng L.; Battelli N.; Nole F.; Montironi R., Renal Cell Carcinoma: genomic landscape and clinical implications, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2020, 5, pp. 95 - 100 [articolo]
Loriot, Y.; Sternberg, C. N.; Castellano, D.; Oosting, S. F.; Dumez, H.; Huddart, R.; Vianna, K.; Gordoa, T. A.; Skoneczna, I.; Fay, A. P.; Nole, F.; Massari, F.; Brasiuniene, B.; Maroto, P.; Fear, S.; Di Nucci, F.; de Ducla, S.; Choy, E., Safety and efficacy of atezolizumab in patients with autoimmune disease: Subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma, «EUROPEAN JOURNAL OF CANCER», 2020, 138, pp. 202 - 211 [articolo]
Massari F.; Mollica V.; Rizzo A.; Cosmai L.; Rizzo M.; Porta C., Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis, «EXPERT OPINION ON DRUG SAFETY», 2020, 19, pp. 1329 - 1338 [articolo]
